Abbott Laboratories Fined
FDA imposes $100 million fine
Abbott Park, Ill-Abbott Laboratories has been fined $100 million by the Food and Drug Administration. The two organizations entered into a consent decree, which does not represent an admission of any violation, but prohibits Abbott from manufacturing or distributing diagnostic products until their Lake County, Ill, manufacturing site conforms with the FDA's Quality System Regulation. The deadline for compliance is one year.
The original decree allowed the products to remain on the market for 30 days, so consumers would have time to find alternate suppliers. However, the US District Court amended the decree upon the request of users and extended the deadline to January 10, 2000. "This decree allows us to resolve these issues comprehensively and systematically without disruption to patient care worldwide. We will work closely and cooperatively with the FDA to ensure our Lake County, Ill, diagnostic manufacturing operations are in full and complete conformance as rapidly as possible," states Miles D. White, chairman and chief executive officer of Abbott Laboratories. The decree does not affect other Abbott products.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
